Some of the targets in cancer research are visible and well known, but they’re hard to hit with new drugs all the same. PIC Therapeutics is developing medicines aiming for one particularly elusive group of proteins, and the startup’s early research has attracted financial support from some prominent names in the life sciences industry.
PIC announced Wednesday that it has raised $5 million in seed financing. The funding round was led by Advent Life Sciences, a London-based investment firm. Individual backers also joined the financing, including Belinda Termeer, the widow of former Genzyme CEO Henri Termeer.
The research of Boston-based PIC… Read more »
UNDERWRITERS AND PARTNERS
